Extracellular matrix fibrotic markers in heart failure

Area of Science:

• Cardiology
• Biomarker Research
• Heart Failure Pathophysiology

Background:

• Fibrous tissue accumulation (fibrosis) is critical in causing myocardial dysfunction and heart failure (HF).
• Non-invasive methods for assessing cardiac fibrosis are needed for clinical utility in HF management.
• Extracellular matrix (ECM) biomarkers show promise for detecting early cardiac and vascular changes preceding or during HF development.

Purpose of the Study:

• To highlight the clinical utility of non-invasive fibrosis assessment in heart failure (HF) patients.
• To explore the role of extracellular matrix (ECM) biomarkers in HF.
• To discuss the potential of biomarkers for early detection, diagnosis, risk stratification, and therapy monitoring in HF.

Main Methods:

• Review of existing literature on cardiac fibrosis and HF biomarkers.
• Focus on extracellular matrix (ECM) biomarkers and their relationship to myocardial structure and function.
• Discussion of serum peptides from collagen metabolism for monitoring treatment effects.

Main Results:

• High ECM biomarker levels correlate with adverse outcomes in HF.
• ECM biomarkers can detect early structural and functional changes in the heart and vasculature.
• Serum peptides from collagen metabolism may indicate treatment efficacy in reducing myocardial fibrosis.

Conclusions:

• Non-invasive fibrosis assessment using ECM biomarkers could be a valuable tool in heart failure (HF) management.
• Biomarkers facilitate early disease detection, diagnosis, risk stratification, and monitoring of therapeutic interventions.
• Monitoring collagen metabolism peptides may track treatment response and guide therapy in HF patients.